Bayer, Zydus Cadila form pharmaceutical joint venture in India

28 January 2011 08:43  [Source: ICIS news]

SINGAPORE (ICIS)--Germany’s Bayer said on Friday that its healthcare business will form a joint venture (JV) with Zydus Cadila of India to enhance its presence in the south Asian country's pharmaceutical industry.

The 50:50 marketing and sales enterprise named Bayer Zydus Pharma will be headquartered in Mumbai, the company said.

Financial details of the transaction were not disclosed.

The JV would have about 600 employees, Bayer said.

"We expect to leverage on the strengths of the joint venture such as the optimized product portfolio and the distribution capabilities to enhance the launch of new products and the sales of existing brands," said Bayer HealthCare CEO Jorg Reinhardt in a statement.

Bayer Zydus Pharma would operate in key segments of the Indian pharmaceutical market, with a focus on women’s healthcare, diagnostic imaging, cardiovascular diseases, anti-diabetic treatments, and oncology.

Its future product portfolio would include in-licensed and originator brands, as well as patented pharmaceuticals from Bayer HealthCare’s pipeline, Bayer said.

To discuss issues facing the chemical industry go to ICIS connect

By: Pearl Bantillo
+65 6780 4359

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly